EcoDrugPlus

Calcitonin Receptor Like Receptor

Ensembl ID : ENSMAUG00000016850
Gene Symbol: CALCRL
3 Cross references
147 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit

Ensembl ID : ENSMAUG00000020160
Gene Symbol: CACNA1D
1 Cross references
281 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha2/delta Subunit 1

Ensembl ID : ENSMAUG00000003964
Gene Symbol: CACNA2D1
1 Cross references
275 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha2/delta Subunit 3

Ensembl ID : ENSMAUG00000012283
Gene Symbol: CACNA2D3
1 Cross references
309 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSMAUG00000012711
Gene Symbol: CACNA2D2
4 Cross references
272 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSMAUG00000010863
Gene Symbol: CACNA2D4
3 Cross references
317 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 1

Ensembl ID : ENSMAUG00000015897
Gene Symbol: CACNB1
4 Cross references
210 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSMAUG00000003823
Gene Symbol: CACNB2
4 Cross references
201 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSMAUG00000012005
Gene Symbol: CACNB3
4 Cross references
275 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 4

Ensembl ID : ENSMAUG00000014567
Gene Symbol: CACNB4
4 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 1

Ensembl ID : ENSMAUG00000001874
Gene Symbol: CACNG1
4 Cross references
264 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSMAUG00000015548
Gene Symbol: CACNG2
4 Cross references
259 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).